October 19, 2024 06:00 AM EDT

A Q&A with a Nobel Prize winner; Pfizer meets with Starboard; J&J reports Q3 earnings; and more

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A Q&A with a Nobel Prize winner; Pfizer meets with Starboard; J&J reports Q3 earnings; and more

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

A conversation with Nobel Prize winner David Baker on the future of AI in protein design — and beyond

Facing a critical week, Pfizer confronts an unsparing foe in Starboard

Eli Lilly reveals £279M investment in the UK through new government deal

Q&A: Sanofi’s R&D head reflects on his first year, a post-Dupixent future, and finding an identity

CVS replaces CEO Karen Lynch with PBM exec David Joyner

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

A Q&A with a No­bel Prize win­ner; Pfiz­er meets with Star­board; J&J re­ports Q3 earn­ings; and more

Senior Editor

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

A Q&A with a Nobel Prize winner; Pfizer meets with Starboard; J&J reports Q3 earnings; and more